返回 
加入收藏
瑞舒伐他汀联合盐酸小檗碱对急性缺血性脑梗死患者相关指标的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | 瑞舒伐他汀联合盐酸小檗碱对急性缺血性脑梗死患者相关指标的影响 |
| TITLE： | |
| 摘要： | 目的：探讨瑞舒伐他汀联合盐酸小檗碱对急性缺血性脑梗死患者相关指标的影响。方法：回顾性分析120例急性缺血性脑梗死患者的病历资料，依据用药不同分为观察组（65例）和对照组（55例）。两组患者均给予常规基础治疗，在此基础上对照组患者给予瑞舒伐他汀钙片10 mg，睡前口服，每日1次；观察组患者在对照组治疗基础上加服盐酸小檗碱片0.3 g，每日3次。两组疗程均为14 d。观察并比较两组患者治疗前后血清总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、超敏C反应蛋白（hs-CRP）和氧化低密度脂蛋白（ox-LDL）水平，美国国立卫生研究院脑卒中量表（NIHSS）评分和日常生活能力评定量表（ADL）评分，颈动脉粥样硬化斑块总面积（TPA）、颈动脉内膜中层厚度（IMT）、颈动脉粥样硬化斑块最大厚度之和（Crouse积分）、不稳定斑块数目和不良反应发生情况等。 结果：治疗前，上述各项指标比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者血清TC、TG、LDL-C、hs-CRP、ox-LDL水平显著低于同组治疗前，且观察组显著低于对照组，差异均有统计学意义（P＜0.05）。治疗后，两组患者NIHSS评分显著低于同组治疗前，ADL评分和血清HDL-C水平显著高于同组治疗前，差异均有统计学意义（P＜0.05）；但各指标组间比较，差异均无统计学意义（P＞0.05）。治疗后，对照组患者IMT、Crouse积分、不稳定斑块数目与治疗前比较，差异无统计学意义（P＞0.05），而观察组患者显著低于同组治疗前（P＜0.05），亦显著低于同期对照组，差异均有统计学意义（P＜0.05）。两组患者治疗前后TPA比较，差异无统计学意义（P＞0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：在常规治疗基础上，瑞舒伐他汀联合盐酸小檗碱能有效降低急性缺血性脑梗死患者血脂水平，稳定或逆转动脉粥样斑块，减轻患者氧化应激与炎症反应，安全性亦较好。 |
| ABSTRACT： | OBJECTIVE： To investigate the effects of rosuvastatin combined with berberine hydrochloride on related indexes in patients with acute cerebral infarction. METHODS： Medical information of 120 patients diagnosed as acute ischemic cerebral infarction were analyzed retrospectively， and they divided into observation group （65 cases） and control group （55 cases） according to route of administration. Both groups were given routine treatment； control group was additionally given Rosuvastatin calcium tablets 10 mg orally before bedtime， once a day； observation group was additionally given Berberine hydrochloride tablets 0.3 g orally， 3 times a day， on the basis of control group. Treatment courses of 2 groups lasted for 14 d. The levels of TC， TG， LDL-C，HDL-C， hs-CRP， ox-LDL， NIHSS score， ADL score， TPA， IMT， Crouse score， the number of unstable plaque and ADR were observed and compared between 2 groups before and after treatment. RESULTS： Before treatment， there was no statistical significance in above indexes between 2 groups （P＞0.05）. After treatment， the serum levels of TC， TG， LDL-C， hs-CRP and ox-LDL in 2 groups were significantly lower than before， and the observation group was significantly lower than the control group， with statistical significance （P＜0.05）. After treatment， NIHSS score of 2 groups were significantly lower than before， and ADL score， HDL-C levels were significantly higher than before， with statistical significance （P＜0.05）； there was no statistical significance between 2 groups （P＞0.05）. After treatment， there was no statistical significance in IMT， Crouse score and the number of unstable plaque in control group compared to before treatment （P＞0.05），but in observation group were significantly lower than before treatment， and also lower than control group at corresponding period， with statistical significance （P＜0.05）. There was no statistical significance in TPA between 2 groups before and after treatment（P＞0.05）. There was no statistical significance in the indcidence of ADR between 2 groups during treatment（P＞0.05）. CONCLUSIONS： Based on routine treatment，rosuvastatin combined with berberine hydrochloride could effectively reduce blood lipid levels in patients with acute cerebral infarction， stabilize or reverse atherosclerotic plaque， and reduce inflammation and oxidative stress with good safety. |
| 期刊： | 2017年第28卷第24期 |
| 作者： | 刘鹏，张敬伟，王尚珍 |
| AUTHORS： | LIU Peng，ZHANG Jingwei，WANG Shangzhen |
| 关键字： | 瑞舒伐他汀；盐酸小檗碱；动脉粥样硬化；脑梗死；炎症因子；血脂 |
| KEYWORDS： | Rosuvastatin； Berberine hydrochloride； Atherosclerotic plaques； Cerebral infraction； Inflammatory factors； Blood lipid |
| 阅读数： | 553 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
